Načítá se...
Novel role of phosphodiesterase inhibitors in the management of end-stage heart failure
In advanced heart failure (HF), chronic inotropic therapy with intravenous milrinone, a phosphodiesterase III inhibitor, is used as a bridge to advanced management that includes transplantation, ventricular assist device implantation, or palliation. This is especially true when repeated attempts to...
Uloženo v:
| Vydáno v: | World J Cardiol |
|---|---|
| Hlavní autoři: | , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Baishideng Publishing Group Inc
2016
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4958691/ https://ncbi.nlm.nih.gov/pubmed/27468333 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4330/wjc.v8.i7.401 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|